Fibrogen Stock Fundamentals
| FGEN Stock | MXN 7.94 0.89 12.62% |
FibroGen fundamentals help investors to digest information that contributes to FibroGen's financial success or failures. It also enables traders to predict the movement of FibroGen Stock. The fundamental analysis module provides a way to measure FibroGen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroGen stock.
FibroGen |
FibroGen Company Profit Margin Analysis
FibroGen's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current FibroGen Profit Margin | (2.94) % |
Most of FibroGen's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, FibroGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, FibroGen has a Profit Margin of -2.9416%. This is 73.76% lower than that of the Healthcare sector and 87.23% lower than that of the Biotechnology industry. The profit margin for all Mexico stocks is 131.62% higher than that of the company.
FibroGen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining FibroGen's current stock value. Our valuation model uses many indicators to compare FibroGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across FibroGen competition to find correlations between indicators driving FibroGen's intrinsic value. More Info.FibroGen is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value FibroGen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for FibroGen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.FibroGen Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FibroGen's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FibroGen could also be used in its relative valuation, which is a method of valuing FibroGen by comparing valuation metrics of similar companies.FibroGen is currently under evaluation in profit margin category among its peers.
FibroGen Fundamentals
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.52) % | |||
| Current Valuation | 21.87 B | |||
| Shares Outstanding | 93.96 M | |||
| Shares Owned By Insiders | 7.82 % | |||
| Shares Owned By Institutions | 78.80 % | |||
| Price To Book | 54.45 X | |||
| Price To Sales | 231.63 X | |||
| Revenue | 235.31 M | |||
| Gross Profit | (104.61 M) | |||
| EBITDA | (288.53 M) | |||
| Net Income | (290.02 M) | |||
| Cash And Equivalents | 565.4 M | |||
| Cash Per Share | 6.56 X | |||
| Total Debt | 77.14 M | |||
| Debt To Equity | 15.10 % | |||
| Current Ratio | 6.16 X | |||
| Book Value Per Share | 0.28 X | |||
| Cash Flow From Operations | (82.23 M) | |||
| Earnings Per Share | (62.14) X | |||
| Number Of Employees | 566 | |||
| Beta | 0.85 | |||
| Market Capitalization | 43.36 B | |||
| Total Asset | 773.82 M | |||
| Net Asset | 773.82 M |
About FibroGen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.